Hi,
I apologize for the delay in replying.
The following reply has been written by Dr Paul S, MD.
This is a case where we may be dealing with a recurrent
cervical cancer with uterine extension, or a second primary
cancer (uterine cancer). Either case, a repeat radiation therapy
may not be feasible
since the pelvis can only tolerate a certain dose of radiation.
If the patient's medical condition can be improved through diet
up building, albumin and RBC transfusions, control of
co-morbidities, the ideal treatment option would be surgical
removal (THBSO, with para-aortic lymph node dissection, or
maximal debulking)per the latest NCCN guidelines on uterine
cancer. The scans show that the tumor is not infiltrating the
rectum and the urinary organs so the surgeon may have a good
chance of isolating the tumor and resecting it completely.
However, it should be well explained to the patient that this
approach carries significant risk since she has other
comorbidities. Post operative chemotherapy (adjuvant) may be
warranted depending on the surgical findings.
If the risks are unacceptable to the patient, then palliative
chemotherapy is the next best option. Chemotherapy for uterine
cancer includes platinum agents, used singly or in combination.
Most commonly used combination regimen is Paclitaxel+Carboplatin
or Cisplatin+Doxorubicin. However, the patient's performance
status may affect our judgment to use these combination treatment
and we may
limit ourselves in using single agent chemotherapy (either
paclitaxel, carboplatin, cisplatin or doxorubicin used singly).
The patient's hemoglobin and nutritional status should all be
addressed before starting chemotherapy. The side-effects of each
drug should also be well explained (Cisplatin=nephrotoxicity,
paclitaxel+carboplatin=neutropenia, doxorubicin=neutropenia and
cardiotoxicity).
Another option for the patient's treatment is the use of hormonal
therapy. This form of treatment offers the advantage of efficacy
with a favorable side-effect profile. Present guidelines
recommend the use of progestational agents,tamoxifen, or
aromatase inhibitors (letrozole, anastrozole, exemestane). These
agents are used for patients who may not be able to tolerate
invasive procedures such as surgery or cytotoxic treatment
(chemotherapy).
The goal of treatment should be made clear, whether it is
curative (surgery), or palliative (through chemotherapy
or hormonal therapy), and the risk/benefit ratios assessed and
explained. Informed consent for each option should be
well documented.
Addressing the primary tumor through chemotherapy or hormonal
therapy may eventually relieve the edema. However,
there are other pharmacologic and non-pharmacologic measures to
address the problem. Correcting the patient's
albumin through albumin transfusions or increasing the protein in
the diet may help in decreasing the edema. Compressive
stockings may also decrease the edema as well as exercises like
leg elevation and passive leg movements. Correcting
the hemoglobin levels through transfusions may also improve
overall hemodynamics.
The patient's primary tumor and the edema may be causing a lot of
pain. For this reason pain medications are warranted.
Opioid or opioid like pain relievers (like tramadol, or morphine)
may be ideal since these drugs are less likely to interfere
with the patient's kidney function (she already has a
hydronephrotic right kidney).
The patient may also be on prolonged bed rest and immobilization
and she needs good nursing care to prevent
decubitus ulcers. She may also need venous thrombosis
prophylaxis in the form of low molecular weight heparins
(like clexane) to lower risk of pulmonary embolism.
Antibiotic treatment should be started if highly suspicious for
infection, covering empirically to include urinary pathogens
(gram negatives). If cultures (blood or urine) are able to
isolate a pathogen, antibiotic treatment should be tailored
to address such pathogens.
Detailed answer for your question: Available in paid version. - Click to pay.
Second opinion from another doctor: Available in paid version. - Click to pay.